Arthrex Inc.

What does Arthrex own?

Arthrex owns orthopedic product lines including FiberWire sutures, SwiveLock anchors, biologics systems, and arthroscopy equipment. It sells under a single master brand and does not hold a portfolio of separate consumer brands.

Is Arthrex publicly traded?

No. Arthrex is a private company wholly owned by its founder and has never issued public stock.

Who founded Arthrex?

Reinhold Schmieding founded the company in Munich, Germany, in 1981 and remains its owner and president more than four decades later.

Where is Arthrex headquartered?

Its headquarters and main campus are in Naples, Florida, where it houses corporate offices, US manufacturing, and a large surgeon training center.

How many brands does Arthrex own?

It operates under a single Arthrex master brand, with named product families such as FiberWire and SwiveLock rather than distinct brands.

Who owns Arthrex?

Founder Reinhold Schmieding owns Arthrex outright. There are no outside shareholders, private equity investors, or public owners.

What is Arthrex's revenue?

As a private company Arthrex does not publish audited revenue. Third-party estimates place annual revenue at approximately 3.2 billion dollars, and it reports more than 13,000 employees globally.

Reinhold Schmieding founded Arthrex in Munich, Germany, in 1981, starting as a distributor of arthroscopy instruments. He had seen the emerging field of minimally invasive joint surgery during his father's orthopedic practice and recognized that the instruments available were limited for the procedures surgeons wanted to perform.

The company moved its base to the United States, initially in Connecticut and later to Florida, shifting from distribution to designing and manufacturing its own devices. The name comes from arthroscopy, the technique that has remained the core of its identity.

Through the 1990s and 2000s Arthrex expanded into a full product manufacturer, introducing fixation systems, suture anchors, and biologics while building a global subsidiary network. Its headquarters relocated to Naples, Florida, where a large campus now houses corporate offices, manufacturing, and a surgeon training center that hosts thousands of visiting clinicians each year.

By the 2020s Arthrex had grown into one of the largest privately held medical device companies in the world, with more than 13,000 employees and products in over 100 countries. It continues to invest heavily in US manufacturing, including a large expansion of its Florida production capacity, while its founder retains control at the age of 70.

Arthrex reports corporate responsibility efforts centered on US manufacturing, workforce investment, and surgical education. Its main campus in Naples runs manufacturing and training operations that anchor local employment, and it emphasizes environmental programs at its facilities.

The relevant ethical framework is medical device regulation rather than consumer standards. Its products are subject to FDA and international device rules, and its surgeon training model, while a commercial advantage, also operates within professional education norms that carry their own compliance obligations around industry-physician relationships.

Arthrex has faced scrutiny typical of a large device maker, including product field actions and FDA communications over the years, but no defining safety scandal. Its devices, like all implants, carry ongoing post-market surveillance obligations.

As a private company it receives less financial scrutiny than public peers, though its size and founder control periodically draw attention in industry coverage of independent device makers. Legal disputes in orthopedics, including patent and trade matters, are a normal feature of its competitive environment.